About Dr. Oliver Medvedik

Oliver Medvedik, Co-founder of Genspace citizen science laboratory in Brooklyn NY, earned his Ph.D. at Harvard Medical School in the Biomedical and Biological Sciences program. As part of his doctoral work he has used single-celled budding yeast as a model system to map the genetic pathways that underlie the processes of aging in more complex organisms, such as humans. Prior to arriving in Boston for his doctoral studies, he has lived most of his life in New York City. He obtained his bachelor’s degree in biology from Hunter College, City University of New York. Since graduating from Harvard, he has worked as a biotechnology consultant, taught molecular biology to numerous undergraduates at Harvard University and mentored two of Harvard’s teams for the international genetically engineered machines competition (IGEM) held annually at M.I.T.
Posts from the author

On April 30th at 13:00 EST the Journal Club will be discussing the recent paper from the Salk Institute. The findings, published in the journal Nature Medicine, showcase a novel CRISPR/Cas9 genome-editing therapy that can suppress the accelerated aging observed in mice with Hutchinson-Gilford progeria syndrome. This treatment provides an important insight into the molecular pathways…

The March Journal Club hosted by Dr. Oliver Medvedik focused on a recent study that showed transplanting the bone marrow of young laboratory mice into old mice prevented cognitive decline in the old mice, preserving their memory and learning abilities. These findings support the idea that cognitive decline is in part due to the aging of blood cells,…

The March Journal Club hosted by Dr. Oliver Medvedik will focus on this recent study that showed transplanting the bone marrow of young laboratory mice into old mice prevented cognitive decline in the old mice, preserving their memory and learning abilities. These findings support the idea that cognitive decline is in part due to the aging of…

The February journal club focused on the recent paper “Genomics of 1 million parent lifespans implicates novel pathways and common diseases and distinguishes survival chances”. Hosted by Dr. Oliver Medvedik, we were joined by study author, Dr. Peter Joshi from the University of Edinburgh, UK, who guides us through this fascinating genomics study of human…

For the January Journal Club, we discussed the recent human senolytics trial conducted at the Mayo Clinic. Abstract Background Cellular senescence is a key mechanism that drives age-related diseases, but has yet to be targeted therapeutically in humans. Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal cellular senescence-associated disease. Selectively ablating senescent cells using dasatinib plus quercetin…

For the January Journal Club, we will be taking a look at the recent human senolytics trial conducted at the Mayo Clinic. Abstract Background Cellular senescence is a key mechanism that drives age-related diseases, but has yet to be targeted therapeutically in humans. Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal cellular senescence-associated disease. Selectively…

The topic for the December Journal Club was the recently published paper Fisetin is a senotherapeutic that extends health and lifespan. This commonly available supplement, a plant-based polyphenol, appears to influence aging in mice by clearing senescent cells, which are one of the hallmarks of aging. There is certainly plenty of justification for moving this compound…

The topic for the December Journal Club will be the recently published paper – Fisetin is a senotherapeutic that extends health and lifespan. This commonly available supplement and a plant-based polyphenol appears to influence the aging process in mice by clearing senescent cells, one of the suggested reasons we age. There is certainly plenty of justification…

Tau protein aggregation is associated with cellular senescence in the brain is the topic for the November Journal Club. This is an important paper as it shows how senescent cells contribute to Alzheimer’s disease and how removing them appears to improve the condition. Dr. Oliver Medvedik, Steve Hill, and Victor Bjoerk discussed this interesting study…

The October Journal Club focused on a new study in worms where a combination of compounds acted in synergy to almost double lifespan. SUMMARY There is growing interest in pharmacological interventions directly targeting the aging process. Pharmacological interventions against aging should be efficacious when started in adults and, ideally, repurpose existing drugs. We show that…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD